Engineered probiotics as live biotherapeutics for diagnosis and treatment of human diseases

References

• Aggarwal N, Breedon AME, Davis CM, Hwang IY, Chang MW. 2020. Engineering probiotics for therapeutic applications: recent examples and translational outlook. Curr Opin Biotechnol. 65:171–179.
   PubMed Web of Science ®Google Scholar
• Aldridge DR, Tranah EJ, Shawcross DL. 2015. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 5(Suppl 1):S7–S20.
   PubMedGoogle Scholar
• Amalaradjou MAR, Bhunia AK. 2013. Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered. 4(6):379–387.
   PubMed Web of Science ®Google Scholar
• Barra M, Danino T, Garrido D. 2020. Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Front Bioeng Biotechnol. 8:265.
   PubMed Web of Science ®Google Scholar
• Begley M, Hill C, Gahan CG. 2006. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 72(3):1729–1738.
   PubMed Web of Science ®Google Scholar
• Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, Deelen P, Vatanen T, Schirmer M, Smeekens SP, et al. 2016. The effect of host genetics on the gut microbiome. Nat Genet. 48(11):1407–1412.
   PubMed Web of Science ®Google Scholar
• Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, Neumann J, James MJ, Geiger S, Jin WJ, et al. 2021. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 598(7882):662–666.
   PubMed Web of Science ®Google Scholar
• Cao H, Zhou TY, Tang HB, Feng PY, Ali G, Liu P, Li XK. 2021. Genetically encoded probiotic EcN 1917 alleviates alcohol-induced acute liver injury and restore gut microbiota homeostasis. J Funct Foods. 85:104661.
   Web of Science ®Google Scholar
• Carvalho AL, Miquel-Clopes A, Wegmann U, Jones E, Stentz R, Telatin A, Walker NJ, Butcher WA, Brown PJ, Holmes S, et al. 2019. Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization. Clin Exp Immunol. 196(3):287–304.
   PubMed Web of Science ®Google Scholar
• Cecarini V, Bonfili L, Gogoi O, Lawrence S, Venanzi FM, Azevedo V, Mancha-Agresti P, Drumond MM, Rossi G, Berardi S, et al. 2020. Neuroprotective effects of p62 (SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study. Aging-US. 12(16):15995–16020.
   Web of Science ®Google Scholar
• Chang WW, Lee CH. 2014. Salmonella as an innovative therapeutic antitumor agent. IJMS. 15(8):14546–14554.
   Google Scholar
• Chen JH, Li XH, Liu YM, Su TY, Lin CS, Shao LJ, Li LH, Li WW, Niu GY, Yu J, et al. 2021. Engineering a probiotic strain of Escherichia coli to induce the regression of colorectal cancer through production of 5-aminolevulinic acid. Microb Biotechnol. 14(5):2130–2139.
   PubMed Web of Science ®Google Scholar
• Chen KV, Zhu YX, Zhang YR, Hamza T, Yu H, Saint Fleur A, Galen J, Yang ZY, Feng HP. 2020. A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Sci Transl Med. 12(567):eaax4905.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. 2019. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 25(7):1057–1063.
   PubMed Web of Science ®Google Scholar
• Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. 2006. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 55(12):1760–1767.
   PubMed Web of Science ®Google Scholar
• Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 104(18):7617–7621.
   PubMed Web of Science ®Google Scholar
• Costabile A, Buttarazzi I, Kolida S, Quercia S, Baldini J, Swann JR, Brigidi P, Gibson GR. 2017. An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. PLoS ONE. 12(12):e0187964.
   PubMed Web of Science ®Google Scholar
• Cuello-Garcia CA, Brożek JL, Fiocchi A, Pawankar R, Yepes-Nuñez JJ, Terracciano L, Gandhi S, Agarwal A, Zhang Y, Schünemann HJ. 2015. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 136(4):952–961.
   PubMed Web of Science ®Google Scholar
• Culligan EP, Hill C, Sleator RD. 2009. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 1(1):9.
   PubMedGoogle Scholar
• Drolia R, Amalaradjou MAR, Ryan V, Tenguria S, Liu D, Bai X, Xu L, Singh AK, Cox AD, Bernal-Crespo V, et al. 2020. Receptor-targeted engineered probiotics mitigate lethal Listeria infection. Nat Commun. 11(1):6344.
   PubMed Web of Science ®Google Scholar
• Durrer KE, Allen MS, von Herbing IH. 2017. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS ONE. 12(5):e0176286.
   PubMed Web of Science ®Google Scholar
• Evivie SE, Huo GC, Igene JO, Bian X. 2017. Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics. Food Nutr Res. 61(1)UNSP:1318034.
   PubMed Web of Science ®Google Scholar
• Fang X, Zhou XT, Miao YQ, Han YW, Wei J, Chen TT. 2020. Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease. AMB Expr. 10(1):80.
   PubMed Web of Science ®Google Scholar
• Fernandez EM, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. 2011. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. 60(8):1050–1059.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, et al. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 469(7331):543–547.
   PubMed Web of Science ®Google Scholar
• Gao XW, Ma YY, Wang Z, Bai J, Jia S, Feng BH, Jiang YP, Cui W, Tang LJ, Li YJ, et al. 2019. Oral immunization of mice with a probiotic Lactobacillus casei constitutively expressing the alpha-toxoid induces protective immunity against Clostridium perfringens alpha-toxin. Virulence. 10(1):166–179.
   PubMed Web of Science ®Google Scholar
• Geldart KG, Kommineni S, Forbes M, Hayward M, Dunny GM, Salzman NH, Kaznessis YN. 2018. Engineered E. coli Nissle 1917 for the reduction of vancomycin-resistant Enterococcus in the intestinal tract. Bioeng Transl Med. 3(3):197–208.
   PubMed Web of Science ®Google Scholar
• Gruner D, Paris S, Schwendicke F. 2016. Probiotics for managing caries and periodontitis: systematic review and meta-analysis. J Dent. 48:16–25.
   PubMed Web of Science ®Google Scholar
• Hafid NA, Christodoulou J. 2015. Phenylketonuria: a review of current and future treatments. Transl Pediatr. 4(4):304–317.
   PubMed Web of Science ®Google Scholar
• He L, Yang H, Tang J, Liu Z, Chen Y, Lu B, He H, Tang S, Sun Y, Liu F, et al. 2019. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J Biol Eng. 13(1):58.
   PubMedGoogle Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. 2014. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11(8):506–514.
   PubMed Web of Science ®Google Scholar
• Ho CL, Tan HQ, Chua KJ, Kang A, Lim KH, Ling KL, Yew WS, Lee YS, Thiery JP, Chang MW. 2018. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat Biomed Eng. 2(1):27–37.
   PubMed Web of Science ®Google Scholar
• Hoffmann DE, Fraser CM, Palumbo F, Ravel J, Rowthorn V, Schwartz J. 2014. Probiotics: achieving a better regulatory fit. Food Drug Law J. 69(2):237–272.
   PubMed Web of Science ®Google Scholar
• Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, Millet YA, Anderson CL, Li N, Fisher AB, West KA, et al. 2018. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol. 36(9):857–864.
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Holowko MB, Yeoh JW, Lim S, Poh CL. 2017. Repurposing a two-component system-based biosensor for the killing of Vibrio cholerae. ACS Synth Biol. 6(7):1403–1415.
   PubMed Web of Science ®Google Scholar
• Jeong H, Arif B, Caetano-Anolles G, Kim KM, Nasir A. 2019. Horizontal gene transfer in human-associated microorganisms inferred by phylogenetic reconstruction and reconciliation. Sci Rep. 9(1):5953.
   PubMedGoogle Scholar
• Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CGM. 2014. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA. 111(20):7421–7426.
   PubMed Web of Science ®Google Scholar
• Kaikiri H, Miyamoto J, Kawakami T, Park SB, Kitamura N, Kishino S, Yonejima Y, Hisa K, Watanabe J, Ogita T, et al. 2017. Supplemental feeding of a gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, alleviates spontaneous atopic dermatitis and modulates intestinal microbiota in NC/nga mice. Int J Food Sci Nutr. 68(8):941–951.
   PubMed Web of Science ®Google Scholar
• Kailasapathy K, Chin J. 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol. 78(1):80–88.
   PubMed Web of Science ®Google Scholar
• Karimi O, Pena AS. 2008. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease. J Clin Gastroenterol. 42(Supplement 3):S136–S141.
   PubMedGoogle Scholar
• Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, et al. 2019. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med. 11(475):eaau7975.
   PubMed Web of Science ®Google Scholar
• Lee JW, Chan CTY, Slomovic S, Collins JJ. 2018. Next-generation biocontainment systems for engineered organisms. Nat Chem Biol. 14(6):530–537.
   PubMed Web of Science ®Google Scholar
• Leonard JV, Morris AAM. 2002. Urea cycle disorders. Semin Neonatol. 7(1):27–35.
   PubMedGoogle Scholar
• Lubkowicz D, Ho CL, Hwang IY, Yew WS, Lee YS, Chang MW. 2018. Reprogramming probiotic Lactobacillus reuteri as a biosensor for Staphylococcus aureus derived AIP-I detection. ACS Synth Biol. 7(5):1229–1237.
   PubMed Web of Science ®Google Scholar
• Li J, Wang W, Xu SX, Magarvey NA, McCormick JK. 2011. Lactobacillus reuteri-produced cyclic dipeptides quench agr-mediated expression of toxic shock syndrome toxin-1 in staphylococci. Proc Natl Acad Sci USA. 108(8):3360–3365.
   PubMed Web of Science ®Google Scholar
• Lin YP, Tibodeaux CH, Pena JA, Ferry GD, Versalovic J. 2008. Probiotic Lactobacillus reuteri suppress proinfammatory cytokines via c-Jun. Infamm Bowel Dis. 14(8):1068–1083.
   PubMed Web of Science ®Google Scholar
• Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. 2003. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 52(6):827–833.
   PubMed Web of Science ®Google Scholar
• Mao N, Cubillos-Ruiz A, Cameron DE, Collins JJ. 2018. Probiotic strains detect and suppress cholera in mice. Sci Transl Med. 10(445):eaao2586.
   PubMed Web of Science ®Google Scholar
• Mathipa MG, Thantsha MS. 2017. Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. Gut Pathog. 9(1):28.
   PubMedGoogle Scholar
• Matsuguchi T, Takagi A, Matsuzaki T, Nagaoka M, Ishikawa K, Yokokura T, Yoshikai Y. 2003. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol. 10(2):259–266.
   PubMedGoogle Scholar
• Mandal SM, Silva ON, Franco OL. 2014. Recombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients. Drug Discov Today. 19(8):1045–1050.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Evans CT, Goldstein EJC. 2018. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 5:124.
   PubMed Web of Science ®Google Scholar
• McKay R, Hauk P, Quan D, Bentley WE. 2018. Development of cell-based sentinels for nitric oxide: ensuring marker expression and unimodality. ACS Synth Biol. 7(7):1694–1701.
   PubMed Web of Science ®Google Scholar
• McKay R, Ghodasra M, Schardt J, Quan D, Pottash AE, Shang W, Jay SM, Payne GF, Chang MW, March JC, et al. 2018. A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: toward applications for Crohn’s disease. Bioeng Transl Med. 3(3):209–221.
   PubMed Web of Science ®Google Scholar
• Medellin-Peña MJ, Wang H, Johnson R, Anand S, Griffiths MW. 2007. Probiotics affect virulence-related gene expression in Escherichia coli O157: h 7. Appl Environ Microbiol. 73(13):4259–4267.
   PubMed Web of Science ®Google Scholar
• Meng J, Wang BY, Liu DY, Chen T, Wang ZW, Zhao XM. 2016. High-yield anaerobic succinate production by strategically regulating multiple metabolic pathways based on stoichiometric maximum in Escherichia coli. Microb Cell Fact. 15(1):141.
   PubMed Web of Science ®Google Scholar
• Michael DV, Anna S, Bernd R, Susanne F, Christiane L, Jurgen S. 2001. Probiotics-compensation for lactase insufficiency. Am J Clin Nutr. 73:421S–4429. S.
   PubMed Web of Science ®Google Scholar
• Mimee M, Citorik RJ, Lu TK. 2016. Microbiome therapeutics-Advances and challenges. Adv Drug Deliver Rev. 105:44–54.
   PubMed Web of Science ®Google Scholar
• Nagamani S, Sahoo R, Muneeswaran G, Narahari Sastry G. 2019. Data science driven drug repurposing for metabolic disorders. In: Roy K, editor. Silico drug design. Academic Press. p. 191–227.
   Google Scholar
• Oh JH, Schueler KL, Stapleton DS, Alexander LM, Yen CLE, Keller MP, Attie AD, van Pijkeren JP. 2020. Secretion of recombinant interleukin-22 by engineered Lactobacillus reuteri reduces fatty liver disease in a mouse model of diet-induced obesity. Msphere. 5(3):e00183-20.
   PubMed Web of Science ®Google Scholar
• Ohland CL, Macnaughton WK. 2010. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 298(6):G807–G819.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S. 2004. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 53(5):685–693.
   PubMed Web of Science ®Google Scholar
• Palma ML, Garcia-Bates TM, Martins FS, Douradinha B. 2019. Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate gag-specific memory CD8(+) T cells ex vivo. Appl Microbiol Biotechnol. 103(13):5461–5461.
   PubMed Web of Science ®Google Scholar
• Palmer JD, Piattelli E, McCormick BA, Silby MW, Brigham CJ, Bucci V. 2018. Engineered probiotic for the inhibition of Salmonella via tetrathionate-induced production of microcin H47. ACS Infect Dis. 4(1):39–45.
   PubMed Web of Science ®Google Scholar
• Peng MF, Tabashsum Z, Patel P, Bernhardt C, Biswas D. 2018. Linoleic acids overproducing Lactobacillus casei limits growth, survival, and virulence of Salmonella Typhimurium and enterohaemorrhagic Escherichia coli. Front Microbiol. 9:2663.
   PubMed Web of Science ®Google Scholar
• Plavec TV, Kuchař M, Benko A, Lišková V, Černý J, Berlec A, Malý P. 2019. Engineered Lactococcus lactis secreting IL-23 receptor-targeted REX protein blockers for modulation of IL- 23/Th17-mediated inflammation. Microorganisms. 7(5):152.
   PubMed Web of Science ®Google Scholar
• Ramirez AM, Rodriguez-Lopez A, Ardila A, Beltran L, Patarroyo CA, Melendez ADP, Sanchez OF, Almeciga-Diaz CJ. 2017. Production of human recombinant phenylalanine hydroxylase in Lactobacillus plantarum for gastrointestinal delivery. Eur J Pharm Sci. 109:48–55.
   PubMed Web of Science ®Google Scholar
• Reis DJ, Ilardi SS, Punt SEW. 2018. The anxiolytic effect of probiotics: a systematic review and meta-analysis of the clinical and preclinical literature. PLoS ONE. 13(6):e0199041.
   PubMed Web of Science ®Google Scholar
• Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-Perez N, Ziegler M, Grant R, Moriarty TF, et al. 2016. The surface-associated exopolysaccharide of Bifdobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local T17 responses. Appl Environ Microbiol. 82(24):7185–7196.
   PubMed Web of Science ®Google Scholar
• Scott BM, Gutiérrez-Vázquez C, Sanmarco LM, da Silva Pereira JA, Li Z, Plasencia A, Hewson P, Cox LM, O’Brien M, Chen SK, et al. 2021. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease. Nat Med. 27(7):1212–1222.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Kao JY, Young VB. 2015. The gut microbiome in health and disease. Curr Opin Gastroenterol. 31(1):69–75.
   PubMed Web of Science ®Google Scholar
• Singh TP, Natraj BH. 2021. Next-generation probiotics: a promising approach towards designing personalized medicine. Crit Rev Microbiol. 47(4):479–498.
   PubMed Web of Science ®Google Scholar
• Smith JL, Fratamico PM, Novak JS. 2004. Quorum sensing: a primer for food microbiologists. J Food Prot. 67(5):1053–1070.
   PubMed Web of Science ®Google Scholar
• Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. 2018. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS ONE. 13(12):e0209205.
   PubMed Web of Science ®Google Scholar
• Sola-Oladokun B, Culligan EP, Sleator RD. 2017. Engineered probiotics: applications and biological containment. Annu Rev Food Sci Technol. 8(1):353–370.
   PubMedGoogle Scholar
• Stritzker J, Szalay AA. 2013. Single-agent combinatorial cancer therapy. Proc Natl Acad Sci USA. 111(21):8325–8326.
   Google Scholar
• Suez J, Zmora N, Segal E, Elinav E. 2019. The pros, cons, and many unknowns of probiotics. Nat Med. 25(5):716–729.
   PubMed Web of Science ®Google Scholar
• Suraweera D, Sundaram V, Saab S. 2016. Evaluation and management of hepatic encephalopathy: current status and future directions. Gut Liver. 10(4):509–519.
   PubMed Web of Science ®Google Scholar
• Tejero-Sarinena S, Barlow J, Costabile A, Gibson GR, Rowland I. 2013. Antipathogenic activity of probiotics against salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic mixtures or the specificity of single strains? Anaerobe. 24:60–65.
   PubMed Web of Science ®Google Scholar
• Thomas CM, Versalovic J. 2010. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes. 1(3):148–163.
   PubMed Web of Science ®Google Scholar
• Tscherner M, Giessen TW, Markey L, Kumamoto CA, Silver PA. 2019. A synthetic system that senses Candida albicans and inhibits virulence factors. ACS Synth Biol. 8(2):434–444.
   PubMed Web of Science ®Google Scholar
• Turroni F, Serafini F, Foroni E, Duranti S, O’Connell Motherway M, Taverniti V, Mangifesta M, Milani C, Viappiani A, Roversi T, et al. 2013. Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium-host interactions. Proc Natl Acad Sci USA. 110(27):11151–11156.
   PubMed Web of Science ®Google Scholar
• Vargason AM, Santhosh S, Anselmo AC. 2020. Surface modifications for improved delivery and function of therapeutic bacteria. Small. 16(25):2001705.
   Web of Science ®Google Scholar
• Volzing K, Borrero J, Sadowsky MJ, Kaznessis YN. 2013. Antimicrobial peptides targeting gram-negative pathogens, produced and delivered by lactic acid bacteria. ACS Synth Biol. 2(11):643–650.
   PubMed Web of Science ®Google Scholar
• von Ossowski I, Pietila TE, Rintahaka J, Nummenmaa E, Makinen VM, Reunanen J, Satokari R, de Vos WM, Palva I, Palva A. 2013. Using recombinant Lactococci as an approach to dissect the immunomodulating capacity of surface piliation in probiotic Lactobacillus rhamnosus GG. PLoS One. 8(5):e64416.
   PubMed Web of Science ®Google Scholar
• Wang LF, Liao Y, Yang RB, Zhu ZF, Zhang LC, Wu ZD, Sun X. 2021. An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis. Bioeng Transl Med. 6(3):e10219.
   PubMed Web of Science ®Google Scholar
• Wang S, Fu W, Zhao X, Chang X, Liu H, Zhou L, Li J, Cheng R, Wu X, Li X, et al. 2022. Mycotoxin disturbs the reproductive-immune axis: the role of gut microbial metabolites. Microbiome. 10(1):234.
   Google Scholar
• Yamada M, Takahashi N, Matsuda Y, Sato K, Yokoji M, Sulijaya B, Maekawa T, Ushiki T, Mikami Y, Hayatsu M, et al. 2018. A bacterial metabolite ameliorates periodontal pathogen-induced gingival epithelial barrier disruption via GPR40 signaling. Sci Rep. 8(1):9008.
   PubMedGoogle Scholar
• Yan F, Cao HW, Cover TL, Whitehead R, Washington MK, Polk DB. 2007. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 132(2):562–575.
   PubMed Web of Science ®Google Scholar
• Yan X, Liu XY, Zhang D, Zhang YD, Li ZH, Liu X, Wu FQ, Chen GQ. 2021. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis. Cell Mol Immunol. 18(10):2344–2357.
   PubMed Web of Science ®Google Scholar
• Yanagihara S, Kanaya T, Fukuda S, Nakato G, Hanazato M, Wu XR, Yamamoto N, Ohno H. 2017. Uromodulin-SlpA binding dictates Lactobacillus acidophilus uptake by intestinal epithelial M cells. Int Immunol. 29(8):357–363.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Y, Lan X, Xu X, Zhang X, Li X, Zhao Y, Li G, Du C, Lu S, et al. 2018. Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice. J Transl Med. 16(1):71.
   PubMedGoogle Scholar
• Zhang RG, Wang C, Cheng WB, Duan GC, Shi QF, Chen SY, Fan QT. 2018. Delivery of Helicobacter pylori HpaA to gastrointestinal mucosal immune sites using Lactococcus lactis and its immune efficacy in mice. Biotechnol Lett. 40(3):585–590.
   PubMed Web of Science ®Google Scholar
• Zheng JH, Nguyen VH, Jiang SN, Park SH, Tan W, Hong SH, Shin MG, Chung IJ, Hong Y, Bom HS. 2017. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 9(376):eaak9537.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen X, Sheng HK, Shen XL, Sun XX, Yan YJ, Wang J, Yuan QP. 2020. Engineering probiotics as living diagnostics and therapeutics for improving human health. Microb Cell Fact. 19(1):56.
   PubMed Web of Science ®Google Scholar